Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1Depressive Disorder 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Antidepressive Agents, Tricyclic × Clear all
NCT01077596 2017-05-30

Carcinogenicity Study of Bupropion

GlaxoSmithKline

Completed
50,430 enrolled 23 charts

Depressive Disorder, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡